ACRS - Aclaris Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 0.96
52-Week Change 3-79.10%
S&P500 52-Week Change 318.08%
52 Week High 39.7500
52 Week Low 30.7400
50-Day Moving Average 31.5942
200-Day Moving Average 32.4559

Share Statistics

Avg Vol (3 month) 31.7M
Avg Vol (10 day) 3406.1k
Shares Outstanding 541.39M
Float 25.06M
% Held by Insiders 17.20%
% Held by Institutions 197.14%
Shares Short (Oct 31, 2019) 46.03M
Short Ratio (Oct 31, 2019) 43.52
Short % of Float (Oct 31, 2019) 419.74%
Short % of Shares Outstanding (Oct 31, 2019) 414.56%
Shares Short (prior month Sep 30, 2019) 42.63M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-1,669.87%

Management Effectiveness

Return on Assets (ttm)-54.84%
Return on Equity (ttm)-145.32%

Income Statement

Revenue (ttm)8.84M
Revenue Per Share (ttm)0.22
Quarterly Revenue Growth (yoy)-12.10%
Gross Profit (ttm)3.24M
EBITDA -145.54M
Net Income Avi to Common (ttm)-168.28M
Diluted EPS (ttm)-4.4570
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)91.43M
Total Cash Per Share (mrq)2.21
Total Debt (mrq)34.42M
Total Debt/Equity (mrq)40.36
Current Ratio (mrq)3.73
Book Value Per Share (mrq)2.06

Cash Flow Statement

Operating Cash Flow (ttm)-103.3M
Levered Free Cash Flow (ttm)-96.81M